SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that company’s product, recombinant humanized anti-IL-17A monoclonal antibody (code: JS005) has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical ...

维多利亚，塞舌尔, Sept. 07, 2025 (GLOBE NEWSWIRE) -- 领先的加密货币交易所和 Web3 公司 Bitget 将与 Saturnia Design 合作举办独家活动 Bitget Elite Day London。 该活动将于 9 月 10 日在 The Royal Society（英国皇家学会）举行，旨在通过关注区块链的发展如何超越投机属性，对现实世界产生可持续的影响，为欧洲数字金融建立切合实际的长远愿景。 去年 6 月，Bitget Elite Day 在布达佩斯大获成功，众多不同领域的业内人士齐聚一堂。伦敦精英日也将以此为基础，进一步加强对话。 这次活动将汇集全球领导者和创新者，旨在直面一个迫在眉睫的关键问题：区块链可以在脱离加密货币的情况下蓬勃发展吗？加密货币在未来十年是否仍保持相关性？ 讨论将由思想领袖小组主导，其中包括 GVG Group 首席执行官兼创始人 Shamit Ghosh 和 Saturnia Design 联合创始人 Mike Vitez。 他们将拨开市场迷雾，探讨一些重要话题，例如去中心化金融 (DeFi) 在传统银行业务中的角色、代币化带来的新 ...

Core Insights - HKC Group makes its European debut at IFA 2025, showcasing innovation across its three brands: HKC, KOORUI, and ANTGAMER [1] - Each brand unveils breakthrough products, emphasizing HKC's commitment to the European market [1] HKC Brand Highlights - HKC introduces the G32M12Max, a 32-inch UHD Mini LED display with over 10,000 local dimming zones, 2100 nits peak brightness, and HDR1400 certification, surpassing mainstream competitors [2] - The G32M12Max features a 240Hz refresh rate, 99% DCI-P3 color coverage, HDMI 2.1, DP 1.4, and 90W USB-C, catering to gamers and creators [2] KOORUI Brand Highlights - KOORUI presents the S4941XO, a 49-inch QD-OLED curved ultra-wide monitor with a 32:9 aspect ratio, 5120×1440 resolution, and 240Hz refresh rate [3] - The S4941XO offers 0.03ms response time, HDR visuals, 98% DCI-P3 coverage, and 10-bit depth, ideal for immersive play and multitasking [3] ANTGAMER Brand Highlights - ANTGAMER unveils the ANT257PF, the world's first mass-produced 750Hz esports monitor, designed for professional tournaments [4] - ANTGAMER also introduces the ANT275ZQE, a 27-inch OLED gaming monitor with dual-mode performance—QHD at 540Hz or HD at 720Hz, featuring DisplayHDR True Black 500 certification [5] Strategic Positioning - By showcasing its three brands together, HKC signals readiness to collaborate with European distributors, retailers, and users [6] - Live demos and hands-on sessions are available at Booth H23-109, with press resources and giveaways for accredited media [6] Company Overview - HKC Group is a global leader in display technology, focusing on advanced R&D, large-scale production, and multi-brand operations [7] - The group aims to deliver innovative monitors for diverse users worldwide, making high-performance displays more accessible [7]

Core Insights - Encaleret demonstrated significant efficacy in normalizing blood and urine calcium levels in post-surgical hypoparathyroidism patients, with 80% achieving normal levels within 5 days of treatment initiation compared to 0% on conventional therapy at baseline [1][6] - The treatment was well-tolerated, with no serious adverse events reported during the study [1] - BridgeBio plans to initiate a registrational clinical study for encaleret in chronic hypoparathyroidism in 2026 based on the promising Phase 2 results [1][3] Company Overview - BridgeBio Pharma, Inc. is focused on developing transformative medicines for genetic diseases, with a pipeline that includes early science to advanced clinical trials [5] - The company was founded in 2015 and aims to leverage advances in genetic medicine to expedite patient care [5] Study Details - The Phase 2 proof-of-concept study evaluated the PTH-independent effects of encaleret on renal calcium handling in ten participants with post-surgical hypoparathyroidism, administered at 162 mg twice daily for up to 5 days [2] - Calcitriol was stopped one day prior to the first dose, and calcium levels were titrated based on blood calcium after starting encaleret [2] Additional Findings - Encaleret treatment resulted in a rapid and sustained reduction in fractional excretion of calcium in nine participants, supporting its potential as an orally-administered treatment option for chronic hypoparathyroidism [6] - Data from preclinical studies of infigratinib were also presented, showing significant improvements in bone growth and skull development in relevant mouse models, indicating broad potential for treating skeletal conditions [4]

Company Overview - TVCMALL is a leading B2B wholesale platform specializing in mobile accessories, showcasing its offerings at IFA 2025 in Berlin [1][18] - The company has 17 years of experience and serves over 30 leading European retail webshops, providing a streamlined approach to sourcing and supply chain management [3][15] Product Offering - TVCMALL offers over 1 million SKUs, with 95% available with no minimum order quantity (MOQ) and 10,000+ new arrivals each week, allowing businesses to respond quickly to market trends [5][13] - The platform features innovative and eco-conscious products, including biodegradable phone cases and VR headset accessories, emphasizing sustainability [6][9] Services Provided - TVCMALL provides a full suite of integrated wholesale services, including real-time sourcing, flexible dropshipping, end-to-end customization, and supply chain enablement [6][12] - The company supports independent online sellers and retail chains with features like private labeling, packaging design, and AI-powered product recommendations [7][8] Strategic Partnerships - TVCMALL collaborates with high-value brands to showcase a diverse range of mobile accessories, enhancing visibility for both brands and buyers [9][10] - The company has established long-term partnerships with brands like DUX DUCIS, JOYROOM, and Lenovo, ensuring stable supply and quality [15] Market Positioning - TVCMALL positions itself as a one-stop wholesale solution, helping retailers save time and reduce costs while simplifying procurement processes [12][16] - The company aims to bridge global buyers with curated products, facilitating strategic procurement and unlocking new growth opportunities [8][19] Future Developments - TVCMALL is expanding its infrastructure and services to better support international customers, including localized service teams and overseas warehouses [20] - The company is committed to eco-friendly practices, including sustainable packaging and production methods, to meet growing market demands [20]

Core Viewpoint - Colabor Group Inc. has entered into forbearance agreements with its principal lenders and Investissement Québec to temporarily avoid defaults related to financial covenants for the third and fourth quarters of 2025 [1][2][3] Group 1: Forbearance Agreements - The forbearance agreements allow Colabor to avoid immediate financial penalties while it works on amendments to its credit facilities [2][3] - The forbearance period is effective until October 15, 2025, contingent on Colabor's compliance with specified financial and operational covenants [3] Group 2: Financial Position and Stability - The agreements provide Colabor with additional flexibility following a cybersecurity incident in July 2025, aimed at strengthening its financial position [4] - Colabor remains committed to normal operations and fulfilling obligations to customers and suppliers while implementing its business plan [4] Group 3: Company Overview - Colabor is a distributor and wholesaler of food products serving the hotel, restaurant, and institutional markets in Quebec and the Atlantic provinces [5]

Core Viewpoint - Hesai Group is launching a global offering of 17,000,000 Class B ordinary shares, which includes a Hong Kong public offering and an international offering, along with a dual-primary listing on the Hong Kong Stock Exchange [1][2]. Offering Details - The global offering consists of 1,700,000 Class B ordinary shares for the Hong Kong public offering and 15,300,000 Class B ordinary shares for the international offering [1]. - The company has an option to issue an additional 2,550,000 Class B ordinary shares, representing 15% of the total shares initially available, to meet excess demand [3][4]. - The initial allocation for the Hong Kong public offering and the international offering is approximately 10% and 90% of the total shares, respectively, with potential adjustments based on oversubscription [5]. Pricing Information - The maximum offer price for the Hong Kong public offering is set at HK$228.00 (approximately US$29.04) per Class B ordinary share [6]. - The final offer price for the international offering will be determined around September 12, 2025, based on market conditions and investor demand [6]. Cornerstone Investments - The company has secured cornerstone investment agreements totaling approximately US$148.0 million, which represents about 29.8% of the shares initially offered [7]. Use of Proceeds - The net proceeds from the global offering will be allocated towards research and development, enhancing manufacturing capabilities, business development, and general corporate purposes [8]. Company Overview - Hesai Technology is a leader in lidar solutions, providing products for various applications including autonomous vehicles and robotics, with a strong focus on R&D and manufacturing integration [13].

Group 1 - Christina Lake Cannabis Corp. has amended the terms of its convertible debentures totaling $710,000, with a new maturity date set for September 7, 2026 [1][2] - The interest rate on the debentures will remain unchanged, and repayments will now occur quarterly starting December 7, 2025, ensuring full repayment by the new maturity date [2] - Holders who did not enter into the amending agreements are expected to be repaid according to the original maturity dates of their debentures [2] Group 2 - Christina Lake Cannabis is a licensed cannabis producer under the Cannabis Act, with a standard cultivation license and a research and development license from Health Canada [3] - The company's facilities include a 32-acre property with over 950,000 square feet of outdoor grow space, and a 342-acre property with approximately 100 acres of licensed outdoor grow space [3] - Christina Lake Cannabis focuses on producing high-quality outdoor flower, extracts, and distillate for its B2B client base [3]

Core Viewpoint - MiniLuxe Holding Corp. plans to issue 345,000 Class A subordinate voting shares at CAD$0.40 per share to settle approximately USD$100,000 in debts owed to Cue Ball Capital, LLC for advisory and consulting services [1][2]. Group 1: Shares for Debt Transaction - The transaction is subject to customary closing conditions, including approval from the TSX Venture Exchange [2]. - All securities issued will have a hold period of four months and one day from the issuance date [2]. Group 2: Related Party Transaction - The transaction is classified as a "related party transaction" due to the involvement of an insider [3]. - The company will rely on exemptions from formal valuation and minority approval requirements under Multilateral Instrument 61-101 [3]. - The shares issued to related parties do not exceed 25% of the company's market capitalization, allowing for exemption from minority approval [3]. Group 3: Company Overview - MiniLuxe is a lifestyle brand and talent empowerment platform in the beauty and self-care industry, focusing on high-quality nail care and esthetic services [5]. - The company aims to transform the self-care and nail care industry through better standards, technology, and a focus on healthier products [5]. - MiniLuxe has performed over 4 million services since its inception, emphasizing professional development and economic mobility for its workforce [5].

Core Viewpoint - Revive Therapeutics Ltd. is extending its private placement offering to raise up to $650,000, with a first tranche already closed generating $60,900 [1][3]. Group 1: Private Placement Details - The private placement consists of up to 30,952,381 units priced at $0.021 per unit, with gross proceeds expected to be up to $650,000 [1]. - A first tranche of 2,900,000 units was issued at the same price, resulting in total gross proceeds of $60,900 [1]. - The company may close an additional $589,000 worth of units as part of this offering [1]. Group 2: Unit Composition and Terms - Each unit includes one common share and one common share purchase warrant, allowing the holder to acquire one common share at an exercise price of $0.05 for 36 months post-closing [2]. - The issue price per unit is based on the 20-day volume-weighted average price (VWAP) of shares traded on the CSE [2]. Group 3: Use of Proceeds - Gross proceeds from the private placement will be allocated for working capital and payment of certain trade payables [3]. - The private placement may close in multiple tranches, subject to customary closing conditions [3]. Group 4: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, leveraging FDA regulatory incentives for rapid advancement [4]. - The company is currently concentrating on Bucillamine for infectious diseases and medical countermeasures, as well as advancing Psilocybin and molecular hydrogen therapeutic programs [4].